HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients.

AbstractBACKGROUND:
Perioral dermatitis (POD) is a common skin disease and difficult to treat. Pimecrolimus cream (1%) successfully controls atopic eczema.
OBJECTIVE:
Our aim was to investigate its efficacy in POD.
STUDY DESIGN:
Single-centre, randomized, double-blind, vehicle-controlled study including 40 POD patients with a 4-week treatment and a 4-week follow-up. Efficacy was assessed by a novel Perioral Dermatitis Severity Index (PODSI) and Finlay's Dermatology Life Quality Index (DLQI).
SETTING:
Outpatient clinics of a large dermatological hospital in Munich, Germany.
RESULTS:
During treatment, the PODSI was significantly lower in the pimecrolimus group compared with vehicle (P = 0.005-0.02) whereas at follow-up, no significant differences were observed. At week 2, the responder rates (> or = 50% PODSI improvement) were 50% with pimecrolimus cream (1%) and 25% with vehicle (P = 0.095). DLQI was improved in pimecrolimus group compared with vehicle.
CONCLUSION:
Results suggest that pimecrolimus cream (1%) effectively treats acute-stage POD.
AuthorsT Oppel, T Pavicic, S Kamann, M Bräutigam, A Wollenberg
JournalJournal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 21 Issue 9 Pg. 1175-80 (Oct 2007) ISSN: 0926-9959 [Print] England
PMID17894701 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Dermatologic Agents
  • pimecrolimus
  • Tacrolimus
Topics
  • Administration, Topical
  • Adolescent
  • Adult
  • Aged
  • Dermatitis, Perioral (drug therapy)
  • Dermatologic Agents (administration & dosage, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Quality of Life
  • Severity of Illness Index
  • Statistics, Nonparametric
  • Tacrolimus (administration & dosage, analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: